-+ 0.00%
-+ 0.00%
-+ 0.00%

Cosmos Health Enters U.S. Market With Launch Of Domestic Manufacturing Via Strategic Partnership With DolCas Biotech

Benzinga·06/24/2025 14:58:25
Listen to the news

Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its entry into the U.S. market and the launch of U.S.-based manufacturing through a strategic agreement with DolCas Biotech LLC ("DolCas"), a New Jersey-based developer and manufacturer of clinically studied nutraceutical ingredients.

Cosmos Health is set to commence production in the United States at GMP-certified (Good Manufacturing Practice) facilities, marking a significant milestone in the Company's operational expansion. This move not only mitigates tariff exposure and cross-border logistical risks but also enhances production control beyond its existing European footprint, positioning Cosmos to scale efficiently in the global healthcare market.

The agreement strengthens Cosmos Health's position in the premium nutraceuticals space and supports its broader strategy to expand its portfolio with scientifically backed, high-efficacy ingredients, while also leveraging DolCas's expertise in clinically validated formulations and vertically integrated manufacturing.